A detailed history of Hya Advisors, Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Hya Advisors, Inc holds 5,791 shares of GILD stock, worth $535,146. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,791
Previous 5,724 1.17%
Holding current value
$535,146
Previous $340,000 5.29%
% of portfolio
0.14%
Previous 0.12%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 13, 2022

BUY
$57.72 - $65.01 $3,867 - $4,355
67 Added 1.17%
5,791 $358,000
Q1 2022

Apr 12, 2022

BUY
$57.92 - $72.58 $4,054 - $5,080
70 Added 1.24%
5,724 $340,000
Q4 2021

Jan 26, 2022

BUY
$64.88 - $73.64 $3,503 - $3,976
54 Added 0.96%
5,654 $411,000
Q1 2020

May 14, 2020

SELL
$62.63 - $80.22 $157,827 - $202,154
-2,520 Reduced 31.03%
5,600 $419,000
Q4 2019

May 04, 2020

BUY
$61.62 - $67.78 $500,354 - $550,373
8,120 New
8,120 $528,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Hya Advisors, Inc Portfolio

Follow Hya Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hya Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hya Advisors, Inc with notifications on news.